Experimental and clinical evidence suggests that mutated or non-functional p53 induces chronic inflammation in cancer cells and promotes an immunosuppressed tumor microenvironment (Cui and Guo, 2016; Agupitan et al., 2020), however it is also a tumor antigen (DeLeo et al., 1979) that can enhance response to immunotherapy (Dong et al., 2017; Biton et al., 2018; Deniger et al., 2018; Chasov et al., 2021). The gene discussed is TP53; the disease is neoplasm.